Limits...
Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer.

Talvinen K, Tuikkala J, Nevalainen O, Rantanen A, Hirsimäki P, Sundström J, Kronqvist P - Br. J. Cancer (2008)

Bottom Line: Our results of a small sample of patients suggest that low securin expression identifies a distinct subgroup of more favourable outcome among patients with high Ki-67 immunoexpression or high MAI.In univariate analysis of Cox's regression, 10-unit increment of securin immunopositivity was associated with a 2.3-fold overall risk of death due to breast cancer and a 7.1-fold risk of death due to breast cancer in the sample of patients stratified according to the cutoff points of 10 and 20% of securin immunopositivity.The finding urges further prognostic studies with a large sample of patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Turku University Hospital, University of Turku, Kiinamyllynkatu 10, FIN-20520 Turku, Finland. kattal@utu.fi

ABSTRACT
We introduce a new proliferation marker, securin (pituitary tumour-transforming 1 (PTTG1)), analysed in invasive ductal breast carcinomas by cDNA microarrays and immunohistochemistry. In cDNA microarray of a total of 4000 probes of genes, securin was revealed with a significant change in expression among the several proliferation-related genes studied. The value of securin as a proliferation marker was verified immunohistochemically (n=44) in invasive ductal breast cancer. In follow-up analyses of the sample of patients, the prognostic value of securin was compared with the established markers of breast cancer proliferation, Ki-67 and mitotic activity index (MAI). Our results of a small sample of patients suggest that low securin expression identifies a distinct subgroup of more favourable outcome among patients with high Ki-67 immunoexpression or high MAI. In univariate analysis of Cox's regression, 10-unit increment of securin immunopositivity was associated with a 2.3-fold overall risk of death due to breast cancer and a 7.1-fold risk of death due to breast cancer in the sample of patients stratified according to the cutoff points of 10 and 20% of securin immunopositivity. We suggest that securin immunostaining is a promising and clinically applicable proliferation marker. The finding urges further prognostic studies with a large sample of patients.

Show MeSH

Related in: MedlinePlus

Kaplan–Meier curves of securin immunohistochemistry distinguish patients with low (<10% securin immunopositivity), intermediate (10–20% securin immunopositivity) and high (>20% securin immunopositivity) risk of death due to breast cancer (n=44) (P=0.0112).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2480969&req=5

fig3: Kaplan–Meier curves of securin immunohistochemistry distinguish patients with low (<10% securin immunopositivity), intermediate (10–20% securin immunopositivity) and high (>20% securin immunopositivity) risk of death due to breast cancer (n=44) (P=0.0112).

Mentions: The results of univariate analysis of Cox's regression with HRs of overall risk of death due to breast cancer are summarised in Table 3 and show statistically significant prognostic value for securin immunohistochemistry and MAI (HRs 2.3 and 1.3, respectively). In our sample, only securin immunohistochemistry demonstrated statistically significant prognostic stratification of patients according to cutoff points of 10 and 20% of breast cancer cells. Among the proliferation markers studied, the highest outcome advantage was associated with securin immunopositivity (HR 7.1, P=0.0270, 95% CI 1.3–40.1, securin >20 vs <10%). In our sample, only securin immunohistochemistry showed statistically significant prognostic value in Kaplan–Meier survival curves (P=0.0112) (Figure 3).


Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer.

Talvinen K, Tuikkala J, Nevalainen O, Rantanen A, Hirsimäki P, Sundström J, Kronqvist P - Br. J. Cancer (2008)

Kaplan–Meier curves of securin immunohistochemistry distinguish patients with low (<10% securin immunopositivity), intermediate (10–20% securin immunopositivity) and high (>20% securin immunopositivity) risk of death due to breast cancer (n=44) (P=0.0112).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2480969&req=5

fig3: Kaplan–Meier curves of securin immunohistochemistry distinguish patients with low (<10% securin immunopositivity), intermediate (10–20% securin immunopositivity) and high (>20% securin immunopositivity) risk of death due to breast cancer (n=44) (P=0.0112).
Mentions: The results of univariate analysis of Cox's regression with HRs of overall risk of death due to breast cancer are summarised in Table 3 and show statistically significant prognostic value for securin immunohistochemistry and MAI (HRs 2.3 and 1.3, respectively). In our sample, only securin immunohistochemistry demonstrated statistically significant prognostic stratification of patients according to cutoff points of 10 and 20% of breast cancer cells. Among the proliferation markers studied, the highest outcome advantage was associated with securin immunopositivity (HR 7.1, P=0.0270, 95% CI 1.3–40.1, securin >20 vs <10%). In our sample, only securin immunohistochemistry showed statistically significant prognostic value in Kaplan–Meier survival curves (P=0.0112) (Figure 3).

Bottom Line: Our results of a small sample of patients suggest that low securin expression identifies a distinct subgroup of more favourable outcome among patients with high Ki-67 immunoexpression or high MAI.In univariate analysis of Cox's regression, 10-unit increment of securin immunopositivity was associated with a 2.3-fold overall risk of death due to breast cancer and a 7.1-fold risk of death due to breast cancer in the sample of patients stratified according to the cutoff points of 10 and 20% of securin immunopositivity.The finding urges further prognostic studies with a large sample of patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Turku University Hospital, University of Turku, Kiinamyllynkatu 10, FIN-20520 Turku, Finland. kattal@utu.fi

ABSTRACT
We introduce a new proliferation marker, securin (pituitary tumour-transforming 1 (PTTG1)), analysed in invasive ductal breast carcinomas by cDNA microarrays and immunohistochemistry. In cDNA microarray of a total of 4000 probes of genes, securin was revealed with a significant change in expression among the several proliferation-related genes studied. The value of securin as a proliferation marker was verified immunohistochemically (n=44) in invasive ductal breast cancer. In follow-up analyses of the sample of patients, the prognostic value of securin was compared with the established markers of breast cancer proliferation, Ki-67 and mitotic activity index (MAI). Our results of a small sample of patients suggest that low securin expression identifies a distinct subgroup of more favourable outcome among patients with high Ki-67 immunoexpression or high MAI. In univariate analysis of Cox's regression, 10-unit increment of securin immunopositivity was associated with a 2.3-fold overall risk of death due to breast cancer and a 7.1-fold risk of death due to breast cancer in the sample of patients stratified according to the cutoff points of 10 and 20% of securin immunopositivity. We suggest that securin immunostaining is a promising and clinically applicable proliferation marker. The finding urges further prognostic studies with a large sample of patients.

Show MeSH
Related in: MedlinePlus